Abstract:
:The management of patients with chronic pain is a common clinical challenge. Indeed, chronic pain is often inadequately controlled in patients with cancer and in those with non-cancer chronic pain. Because of the complex nature of chronic pain, successful long-term treatment is more difficult than for acute pain. Most often acute pain is nociceptive, whereas chronic pain can be nociceptive (i.e., in response to noxious stimuli), neuropathic (i.e., initiated by a primary lesion or dysfunction in the nervous system) or mixed in origin. Opioids are the current standard of care for the treatment of moderate or severe nociceptive pain. Opioids mediate their actions by binding and activating receptors both in the peripheral nervous system and those that are found in inhibitory pain circuits that descend from the midbrain to the spinal cord dorsal horn. Opioid agonists exert a number of physiological responses including analgesia, which increases with increasing doses. The use of opioids to manage pain in patients with cancer is well accepted. The WHO step-wise algorithm for analgesic therapy based on pain severity reserves the use of opioid therapy for moderate and severe pain. The WHO algorithm has proven to be highly effective for the management of cancer pain. However, the use of opioids to treat patients with chronic non-cancer pain is controversial because of concerns about efficacy and safety, and the possibility of addiction or abuse. The results of clinical surveys and retrospective case series involving patients with non-cancer chronic pain have been inconsistent in regard to resolving these controversial issues. The oral route of drug administration is most appropriate for patients receiving opioids; although rectal, transdermal and parenteral routes of administration are used in specific situations. For continuous chronic pain, opioids should be administered around-the-clock and several long-acting formulations are available that require administration only once or twice daily. Opioid doses should be titrated according to agent-specific schedules to maximise pain relief and maintain tolerability. Adverse effects include constipation, nausea and vomiting, sedation, cognitive impairment and respiratory depression. Tolerance to the analgesic and adverse effects as well as physical dependence, which causes withdrawal symptoms upon discontinuance, may occur with opioid use. Estimates of addiction rates among patients with chronic non-cancer pain range from 3.2 to 18.9%. Successful pain treatment and symptom management is an attainable goal for the majority of patients with chronic pain. Further controlled clinical trials are needed to define the role of opioid therapy in chronic non-cancer pain, and to establish criteria for patient selection and specific treatment algorithms.
journal_name
Drugsjournal_title
Drugsauthors
Nicholson Bdoi
10.2165/00003495-200363010-00002subject
Has Abstractpub_date
2003-01-01 00:00:00pages
17-32issue
1eissn
0012-6667issn
1179-1950pii
630102journal_volume
63pub_type
杂志文章,评审相关文献
DRUGS文献大全abstract::Lung tissue remodelling in chronic inflammatory lung diseases has long been regarded as a follow-up event to inflammation. Recent studies have indicated that, although airway and lung tissue remodelling is often independent of inflammation, it precedes or causes inflammation. None of the available therapies has a sign...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-014-0319-0
更新日期:2015-01-01 00:00:00
abstract::Delayed gastric emptying, gastroparesis, is one of the sequelae of diabetes mellitus. Symptoms may include postprandial nausea, epigastric pain, bloating, vomiting, early satiety and unpredictable blood sugar fluctuations. Nowadays diagnosis is made by the measurement of gastric emptying with a radionuclide test meal....
journal_title:Drugs
pub_type: 临床试验,杂志文章,评审
doi:10.2165/00003495-199244040-00002
更新日期:1992-10-01 00:00:00
abstract::Nausea and vomiting is a common and distressing symptom complex in patients with far-advanced cancer, affecting up to 60% of individuals at some stage of their illness. The current approach to the palliative care of patients with nausea and vomiting is based on identifying the cause, understanding its pathophysiology ...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/0003495-200868180-00004
更新日期:2008-01-01 00:00:00
abstract::Systemic therapy for advanced non-small cell lung cancer (NSCLC) has evolved over the last two decades, with modest improvements in quality of life and overall survival. A plateau has been reached with traditional chemotherapy, and efforts are now being directed at developing molecularly targeted agents. To date, thre...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/11532200-000000000-00000
更新日期:2010-01-01 00:00:00
abstract::The endothelium is involved in both the physiological regulation of vascular tone and the structural transformation of the vessel under pathological conditions. Under physiological conditions, endothelial cells continuously secrete nitric oxide (NO), which relaxes smooth muscle cells and ensures vessel patency. Damage...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199700531-00003
更新日期:1997-01-01 00:00:00
abstract::Biologics and biosimilars are medicines made from living cells that treat common and serious diseases such as cancer, diabetes, rheumatoid arthritis, and other inflammatory diseases. They are highly targeted, efficacious, and represent an increasingly important part of physicians' armamentaria in the combat against th...
journal_title:Drugs
pub_type: 杂志文章
doi:10.1007/s40265-018-1009-0
更新日期:2018-11-01 00:00:00
abstract::Specifically formulated for nebulisation using the PARI LC PLUS reusable nebuliser, tobramycin solution for inhalation (TSI) [TOBI] provides a high dose of tobramycin (an aminoglycoside antibacterial with good activity against Pseudomonas aeruginosa) to the lungs of patients with cystic fibrosis, while maintaining low...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200363220-00015
更新日期:2003-01-01 00:00:00
abstract::Viral respiratory tract infections (RTIs) are common causes of mild illness in immunocompetent children and adults, with occasional significant morbidity or mortality in the very young, very old or infirm. However, recipients of solid organ transplants (SOT) or haematopoietic stem cell transplants (HSCT) are at marked...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200767100-00004
更新日期:2007-01-01 00:00:00
abstract::Sotagliflozin (Zynquista™) is the first dual inhibitor of sodium-glucose co-transporter-1 and -2 (SGLT1 and 2). In the phase 3, inTANDEM 1-3 trials, adjunctive use of oral sotagliflozin (200 mg or 400 mg once daily) improved glycaemic control and reduced bodyweight and insulin requirements relative to placebo over 24 ...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-019-01230-w
更新日期:2019-12-01 00:00:00
abstract::Cefdinir (Omnicef) is an oral third-generation cephalosporin with good in vitro activity against many pathogens commonly causative in community-acquired infections. The drug provides good coverage against Haemophilus influenzae, Moraxella catarrhalis and penicillin-susceptible Streptococcus pneumoniae, the most common...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200464130-00004
更新日期:2004-01-01 00:00:00
abstract::The combined oral contraceptive pill is the most popular method of contraception worldwide, with modern low-dose formulations significantly improving tolerability. Breakthrough bleeding is the most significant adverse event associated with the low-dose combined oral contraceptives. Monophasic, biphasic, triphasic and ...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199549020-00007
更新日期:1995-02-01 00:00:00
abstract::Cardiovascular diseases are the leading cause of mortality in industrialized countries. Treatment with statins is effective in primary prevention in patients at high cardiovascular risk. Statins are inhibitors of hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase and are classed as lipid-lowering drugs. In 2010, ato...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/11632010-000000000-00000
更新日期:2012-04-16 00:00:00
abstract::Nivolumab (Opdivo(®)) is a fully human monoclonal antibody against programmed death receptor-1, a negative regulatory checkpoint molecule with a role in immunosuppression. The drug is administered intravenously and is approved for the treatment of unresectable malignant melanoma in Japan. The potential for intravenous...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-014-0234-4
更新日期:2014-07-01 00:00:00
abstract::Intravenous peramivir (Alpivab™; Rapivab®; Rapiacta®; PeramiFlu®), the most recent globally approved inhibitor of influenza neuraminidase, is indicated for the treatment of uncomplicated influenza in adults and children from the age of 2 years. This article, written from an EU perspective, reviews the clinical use of ...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-018-0981-8
更新日期:2018-09-01 00:00:00
abstract::Glatiramer acetate is a synthetic analogue of the multiple sclerosis (MS)-associated antigen, myelin basic protein. It is indicated in the EU, US and many other countries to reduce the frequency of relapses in patients with relapsing-remitting MS (RRMS), and for the treatment of patients who have experienced a well de...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/11204560-000000000-00000
更新日期:2010-08-20 00:00:00
abstract::Saxagliptin (Onglyza™) is a dipeptidyl peptidase 4 inhibitor widely approved for the treatment of type 2 diabetes mellitus. In the EU, saxagliptin is indicated as combination therapy with metformin, a sulfonylurea, a thiazolidinedione, or insulin (with or without metformin) for the treatment of adult patients with typ...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/11208160-000000000-00000
更新日期:2012-01-22 00:00:00
abstract::Through years of evolutionary selection pressures, organisms have developed potent toxins that coincidentally have marked antineoplastic activity. These natural products have been vital for the development of multiagent treatment regimens currently employed in cancer chemotherapy, and are used in the treatment of a va...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-015-0489-4
更新日期:2015-11-01 00:00:00
abstract::Glucocorticoids (GCs) are often used for improvement of quality of life, particularly in the elderly, but long-term GC use may cause harm; bone loss and fractures are among the most devastating side effects. Fracture risk is particularly high in patients with a severe underlying disease with an urgent need for treatme...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-019-01145-6
更新日期:2019-07-01 00:00:00
abstract::Increases in cancer diagnosis have tremendous negative impacts on patients and their families, and major societal and economic costs. The beneficial effect of chemotherapeutic agents on tumor suppression comes with major unwanted side effects such as weight and hair loss, nausea and vomiting, and neuropathic pain. Che...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-019-01132-x
更新日期:2019-06-01 00:00:00
abstract::Pegaspargase (Oncaspar®), a pegylated form of native Escherichia coli-derived L-asparaginase (hereafter referred as E. coliL-asparaginase), is indicated in the USA and EU for the treatment of acute lymphoblastic leukaemia (ALL) as a component of multi-agent chemotherapy in paediatric and adult patients. Relative to E....
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-019-01120-1
更新日期:2019-05-01 00:00:00
abstract::Infections in burn patients continue to be the primary source of morbidity and mortality. Topical antimicrobial therapy remains the single most important component of wound care in hospitalised burn patients. The goal of prophylactic topical antimicrobial therapy is to control microbial colonisation and prevent burn w...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199040030-00004
更新日期:1990-09-01 00:00:00
abstract::Nausea and vomiting continue to be critical problems in cancer chemotherapy, although considerable progress has been made toward understanding the neuropharmacological mechanisms of vomiting and how chemotherapeutic agents and antiemetics affect these mechanisms. The principles of behavioural psychology have also been...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-198734010-00005
更新日期:1987-07-01 00:00:00
abstract::Budesonide MMX(®) (Cortiment(®); Uceris(®)) is a novel once-daily oral formulation of budesonide using Multi Matrix (MMX(®)) colonic delivery technology to permit the release of budesonide at a controlled rate throughout the colon. It is available in the USA for the induction of remission in patients with active, mild...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-015-0396-8
更新日期:2015-05-01 00:00:00
abstract:UNLABELLED:Oral delayed-release mesalazine is an enteric-coated formulation which releases mesalazine in the terminal ileum and colon. Up to 74% of patients with mild to moderately active ulcerative colitis experience endoscopic or symptomatic improvement (including remission) or both when treated with oral delayed-rel...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199957030-00013
更新日期:1999-03-01 00:00:00
abstract::MenB-FHbp (bivalent rLP2086; Trumenba®) is a recombinant protein-based vaccine targeting Neisseria meningitidis serogroup B (MenB), which has recently been licensed in the EU for active immunization to prevent invasive disease caused by MenB in individuals ≥ 10 years of age. The vaccine, which contains a variant from ...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-018-0869-7
更新日期:2018-02-01 00:00:00
abstract::Polyhydric alcohols (polyols) are widely distributed in nature, and the enzymes of the polyol pathway (aldose reductase and sorbitol dehydrogenase) are present in many mammalian tissues. The function of this pathway remains a mystery. A primary role for the pathway in the pathogenesis of 'sugar cataract' was provided ...
journal_title:Drugs
pub_type: 杂志文章
doi:10.2165/00003495-198600322-00003
更新日期:1986-01-01 00:00:00
abstract::Grapefruit juice and grapefruit product consumption have potential health benefits; however, their intake is also associated with interactions with certain drugs, including calcium channel blockers, immunosuppressants and antihistamines. The primary mechanism through which interactions are mediated is mechanism-based ...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/11585250-000000000-00000
更新日期:2010-12-24 00:00:00
abstract:UNLABELLED:Darunavir is an oral nonpeptidic HIV-1 protease inhibitor (PI) that is used, together with a low boosting dose of ritonavir, as part of an antiretroviral therapy (ART) regimen in treatment-experienced and -naive patients with HIV-1 infection. Compared with early-generation PIs, boosted darunavir has a high g...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200969040-00007
更新日期:2009-01-01 00:00:00
abstract::Healthcare systems are in flux throughout the world. Traditional structures and attitudes are changing. The balance of power between political bodies, payers, providers and patients is being destabilised. New approaches by governments and forward integration by drug companies and payers into care management are all ma...
journal_title:Drugs
pub_type: 杂志文章
doi:10.2165/00003495-199600522-00014
更新日期:1996-01-01 00:00:00
abstract::Roxatidine acetate (HOE 760, TZU 0460) is a new H2-receptor antagonist which is more potent than cimetidine and ranitidine. A randomised, double-blind, placebo-controlled study was conducted in healthy men to determine the effects of multiple oral doses of roxatidine acetate on unstimulated gastric acid secretion, and...
journal_title:Drugs
pub_type: 临床试验,杂志文章,随机对照试验
doi:10.2165/00003495-198800353-00011
更新日期:1988-01-01 00:00:00